C5 and myasthenia gravis: Soluble complement receptors improved symptoms in a passive transfer rat model [193], the inhibition of the complement cascade by suppressing the expression of C2 or C5 significantly improved clinical symptoms in a mouse (C2) [194] and rat (C5) [195] model of MG as did the linking of a complement regulator to the motor endplate via coupling to a recombinant AChR antibody [196].